IDEXX LABORATORIES INC /DE Q4 FY2024 earnings call

• IDEXX had a solid finish to 2024 with fourth quarter performance ahead of expectations.
• Organic revenue growth of 6% in Q4, supported by gains in major segments.
• Operating profits increased 7% as reported and 8% on a comparable basis, with gross margin gains.
• Successfully advanced innovation-driven growth strategy, with new product launches like IDEXX inVue Dx and IDEXX Cancer Dx.
• Software business saw double-digit growth in cloud-native PIMS placements and launch of Vello for pet owner engagement.
• Strong commercial execution with high customer retention rates over 97%.

Fourth quarter organic revenue growth was 6%, with solid gains across segments. CAG had 6% organic growth, LPD 7%, and Water 9%. Worldwide CAG Diagnostic recurring revenue increased 7% organically in Q4, including benefits from improved volume growth trends. US CAG Diagnostics recurring revenue increased 4% organically in Q4, net of a 1% negative growth impact from fewer equivalent selling days. International CAG Diagnostic recurring revenue growth was 12% in Q4. VetLab consumable revenues increased 12% organically. Water revenues increased 9% organically in Q4, and Livestock, Poultry and Dairy revenues increased 7% organically in Q4.

• 2025 revenue guidance: $4.055 billion to $4.170 billion, 4%-7% reported growth, 6%-9% organic growth, with ~$50 million and 4,500 placements from IDEXX inVue Dx.
• Operating margin outlook: 31% to 31.5%, 30 basis points to 80 basis points improvement year-over-year.
• EPS outlook: $11.74 per share to $12.24 per share, 8%-12% comparable growth.
• Q1 2025 outlook: Overall organic revenue growth 4%-6%, reported revenue growth 2%-4%, with ~2% negative impact from foreign exchange.

• Macro-economic and sector headwinds affecting clinical visits.
• Foreign exchange impact on revenue and EPS.
• Tariff risk on internationally-sourced materials.

Q: Erin Wright asked about innovation contribution to 2025 guidance, inVue preorder backlog, and FNA launch.

A: Andrew Emerson said guidance includes ~$50 million and 4,500 placements from inVue Dx. Jay Mazelsky noted high customer interest in inVue, controlled launch process, and FNA launch later in 2025.

Q: Chris Schott inquired about vet visit trajectory and US vs ex-US growth.

A: Andrew Emerson said US vet visits expected to decline ~2% in 2025, similar to 2024. Jay Mazelsky highlighted strong international performance, especially Europe with seven consecutive quarters of double-digit CAG Diagnostics recurring revenue growth.

Q: Michael Ryskin asked about wellness visit dispersion and share buyback rationale.

A: Jay Mazelsky said wellness visit quality improved despite dispersion, with diagnostics inclusion growing. Andrew Emerson said share buyback reflects strong free cash flow, healthy balance sheet, and confidence in growth potential.

Q: Jon Block asked about 4Q premium uptick, pricing impact on wellness visits, and interest expense.

A: Brian McKeon said 4Q premium uptick was due to strong consumable growth and international momentum. Jay Mazelsky discussed pricing mindfulness and compliance-based programs. Andrew Emerson explained interest expense aligns with planned share buybacks.

Q: Daniel Clark asked about inVue preorder limits and weather impact on visits.

A: Jay Mazelsky said inVue preorders are generally open but with some international limitations. Andrew Emerson said weather impacts were captured in the outlook.

Q: Navann Ty asked about vet visit factors, margin expansion, and SG&A/R&D with new launches.

A: Jay Mazelsky discussed clinical visit factors like capacity constraints and macroeconomic environment. Andrew Emerson said margin expansion expected to be gross margin-led, with investments in innovation areas.